News
10-08-2008, 03:14 AM
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has completed enrollment in the first stage of a Phase II trial of bavituximab in combination with chemotherapy in patients with advanced breast cancer. This is Peregrine's second Phase II study for the treatment of breast cancer.
More... (http://www.medicalnewstoday.com/articles/124594.php)
More... (http://www.medicalnewstoday.com/articles/124594.php)